P2.16-37 The Introduction of Robotic Lobectomy for Non-Small Cell Lung Cancer in South East Asia: A 5-Year Single Centre Study

Abstract

Kawasaki Medical School. Result: There were 135 eligible patients consisting of 91 male and 44 female, with mean age of 72.1 years (range, 43-87 years). Of 135 patients, 59 patients (43.7%) underwent adjuvant chemotherapy (platinum-based 15, UFT 44). Median followup period was 37.9 months (range 1.1-107.3 months). Overall survival of patients undergoing adjuvant chemotherapy was significantly better compared with that of patients with surgery alone (p¼0.032). There were no differences in recurrence-free survival between the two groups (p¼0.470). Patients who underwent adjuvant chemotherapy with platinum-based regimens survived significantly longer than patients who underwent surgery alone (p¼0.029). Overall survival of patients with platinum-based regimens tended to be better than that of patients with UFT. In a multivariate analysis including sex, age, histologic type, and tumor size, adjuvant chemotherapy was an independent prognostic factor for overall survival (p¼0.037). Conclusion: Adjuvant chemotherapy, especially with platinum-based regimen, provided a significant survival advantage for completely resected stage IB NSCLC.